| Literature DB >> 33262965 |
Thorsten Haas1, Melissa M Cushing2.
Abstract
Acute coagulopathy is prevalent in adult and pediatric trauma patients and is associated with increased morbidity and mortality. While reasonable hypotheses have been created to explain the underlying perturbations of adult trauma coagulopathy (i.e., tissue factor-related increase in thrombin generation, protein C activation, hypoperfusion, and hyperfibrinolysis), only a small number of studies have been performed to prove whether these mechanisms can likewise be detected in pediatric trauma patients. In addition, severe hypofibrinogenemia (<100 mg/dL) is a frequent finding in pediatric trauma patients (>20%). Although the probability of life-threatening coagulopathy is low with minor to moderate injury, it is present in almost all patients with an injury severity score >25, hypotension, hypothermia, and acidosis. As these multifactorial changes in hemostasis cannot be adequately and rapidly measured using standard laboratory testing, the use of viscoelastic measurements has been established in adult trauma management, but prospective studies in children are urgently needed. Apart from diagnostic challenges, several studies have focused on the impact of blood product ratios on the treatment of massively bleeding pediatric trauma patients. The majority of these studies were unable to show improved survival by using higher plasma to red blood cell ratios or higher platelet to red blood cells ratios, but there are no published randomized trials to definitively answer this question. A goal-directed transfusion protocol using viscoelastic tests together with early substitution with an antifibrinolytic and fibrinogen replacement is a promising alternative to traditional ratio-based interventions. Another crucial factor in treating trauma-induced coagulopathy is the early detection of hypofibrinogenemia, a common condition in massively transfused patients. Early treatment of hypofibrinogenemia is associated with improved morbidity and mortality in adults, but needs to be further studied in future pediatric trials. Pediatric trauma patients are not only threatened by coagulopathy-related bleeding but are also at higher risk for venous thromboembolism. Pediatric trauma patients with brain injury, central venous catheters, immobilization, or surgical procedures are at highest risk for developing a deep venous thrombosis. There are no specific pediatric guidelines established to prevent venous thromboembolism in children suffering from traumatic injury.Entities:
Keywords: coagulation factor concentrates; massive bleeding; pediatrics; thrombosis; transfusion; trauma; viscoelastic testing
Year: 2020 PMID: 33262965 PMCID: PMC7687220 DOI: 10.3389/fped.2020.600501
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Signs of trauma-induced coagulopathy using standard laboratory testing (SLT) and viscoelastic testing (VET).
| Impaired initiation of coagulation | Prolonged aPTT | Prolonged R-time (TEG) |
| Weakening of clot strength | Reduced MA (TEG) | |
| Hypofibrinogenemia | Reduced value in Clauss fibrinogen assay | Reduced MA FF (TEG) |
| Hyperfibrinolysis | LY30 ≥ 3% (TEG) |
aPTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio; TEG, thrombelastography; ROTEM, thromboelastometry; R-time, reaction time; CT, clotting time; MA, maximum amplitude; MCF, maximum clot firmness; FF, functional fibrinogen test; FIBTEM, fibrin polymerization assay; LY30, Clot lysis at 30 min after maximum clot strength; ML, maximum lysis at 60 min after CT.
Figure 1This figure illustrates the various potential treatment options for acutely bleeding trauma patients depicting the considerable differences in coagulation testing (SLT, standard laboratory testing; VET, viscoelastic testing), treatment options (ratio-driven vs. goal-directed transfusion), blood components (RBC, red blood cells; FFP, plasma; PLT, platelet concentrates; or CRYO, cryoprecipitate), the use of whole blood (WB), or coagulation factors (Fib, fibrinogen concentrate; PCC, prothrombin complex concentrate; FXIII, factor XIII concentrate).
Figure 2Example of a goal-directed pediatric bleeding management algorithm. TXA, tranexamic acid; RBC, red blood cells; S/D plasma AB, solvent/detergent pooled plasma, blood group AB.